Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biology.
The objective of this analysis is to identify relationships between side-effects, tumor biological factors and response to pre-operative epirubicin and paclitaxel therapy in primary breast cancer. The study was completed for 38 primary breast cancer patients (M0) who received pre-operative epirubicin and paclitaxel chemotherapy. Anemia was controlled by epoetin alfa and did not cause deviations from the planned chemotherapy schedule. There were no severe adverse events, cardiotoxicity or neutropenia. Patients with negative estrogen or progesterone receptors, or high KI-67 suffered more alopecia, while HER2 overexpressing patients had less severe nausea. This pre-operative chemotherapy regimen was well tolerated on the whole; side-effect profiles were correlated with tumor biological factors and also with response.